91.50
0.51%
+0.46
After Hours:
91.50
Natera Inc stock is currently priced at $91.50, with a 24-hour trading volume of 744.98K.
It has seen a +0.51% increased in the last 24 hours and a -0.89% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $91.18 pivot point. If it approaches the $92.91 resistance level, significant changes may occur.
Previous Close:
$91.04
Open:
$91.87
24h Volume:
744.98K
Market Cap:
$11.05B
Revenue:
$1.08B
Net Income/Loss:
$-434.80M
P/E Ratio:
-18.98
EPS:
-4.82
Net Cash Flow:
$-286.15M
1W Performance:
+1.30%
1M Performance:
-0.89%
6M Performance:
+124.32%
1Y Performance:
+72.64%
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
201 Industrial Road, Suite 410, San Carlos, CA
Natera Inc Stock (NTRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-29-23 | Reiterated | BTIG Research | Buy |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-28-23 | Initiated | Bernstein | Mkt Perform |
Jul-05-23 | Resumed | JP Morgan | Overweight |
May-05-23 | Initiated | UBS | Buy |
Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Apr-25-22 | Initiated | Stephens | Overweight |
Mar-08-22 | Initiated | Goldman | Buy |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Jun-15-21 | Initiated | Raymond James | Mkt Perform |
May-25-21 | Initiated | Wells Fargo | Overweight |
Jan-28-21 | Initiated | Truist | Buy |
Oct-08-20 | Initiated | BTIG Research | Buy |
Sep-28-20 | Initiated | Morgan Stanley | Overweight |
Sep-17-20 | Initiated | SVB Leerink | Outperform |
Jun-10-20 | Resumed | Piper Sandler | Overweight |
May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-05-18 | Initiated | JP Morgan | Neutral |
Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
Nov-10-16 | Reiterated | The Benchmark Company | Buy |
May-23-16 | Reiterated | The Benchmark Company | Buy |
May-11-16 | Reiterated | The Benchmark Company | Buy |
Apr-19-16 | Initiated | The Benchmark Company | Buy |
Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-04-15 | Initiated | Robert W. Baird | Outperform |
Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
Jul-27-15 | Initiated | Piper Jaffray | Overweight |
Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Cracking The Code: Understanding Analyst Reviews For Natera
Benzinga
Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades'
Benzinga
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
Zacks Investment Research
Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday?
Benzinga
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
Zacks Investment Research
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
Benzinga
Natera Inc Stock (NTRA) Financials Data
Natera Inc (NTRA) Revenue 2024
NTRA reported a revenue (TTM) of $1.08 billion for the quarter ending December 31, 2023, a +31.99% rise year-over-year.
Natera Inc (NTRA) Net Income 2024
NTRA net income (TTM) was -$434.80 million for the quarter ending December 31, 2023, a +20.63% increase year-over-year.
Natera Inc (NTRA) Cash Flow 2024
NTRA recorded a free cash flow (TTM) of -$286.15 million for the quarter ending December 31, 2023, a +40.28% increase year-over-year.
Natera Inc (NTRA) Earnings per Share 2024
NTRA earnings per share (TTM) was -$3.79 for the quarter ending December 31, 2023, a +31.96% growth year-over-year.
Natera Inc Stock (NTRA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Chapman Steven Leonard | CEO AND PRESIDENT |
Apr 23 '24 |
Sale |
91.38 |
2,552 |
233,200 |
230,319 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Apr 23 '24 |
Sale |
91.38 |
1,523 |
139,171 |
73,039 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Apr 23 '24 |
Sale |
91.38 |
787 |
71,915 |
205,552 |
Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Apr 23 '24 |
Sale |
91.38 |
531 |
48,522 |
117,029 |
Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
Apr 23 '24 |
Sale |
91.38 |
522 |
47,700 |
111,677 |
Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Apr 16 '24 |
Sale |
90.82 |
80,000 |
7,265,651 |
117,560 |
Chapman Steven Leonard | CEO AND PRESIDENT |
Apr 15 '24 |
Sale |
93.13 |
6,816 |
634,797 |
227,710 |
Sheena Jonathan | CO-FOUNDER |
Apr 03 '24 |
Sale |
92.47 |
26,700 |
2,468,822 |
321,031 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Apr 02 '24 |
Sale |
92.62 |
1,378 |
127,629 |
70,646 |
Chapman Steven Leonard | CEO AND PRESIDENT |
Mar 28 '24 |
Sale |
90.42 |
2,662 |
240,687 |
234,526 |
About Natera Inc
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. Natera, Inc. has collaboration partnership with Fox Chase Cancer Center to assess customized circulating tumor DNA assay for recurrence monitoring of kidney cancer; and clinical trial collaboration with Neon Therapeutics, Inc. to assess the treatment response to personal cancer vaccine. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Cap:
|
Volume (24h):